Clinical trials for cancer patients
The Clínica is the private center that promotes the most clinical trials in Spain. We aim to generate knowledge to change the course of diseases.
-
May 8, 2025Pamplona/MadridIn recruitment
ANT-008 Trial comparing the effect of abelacimab relative to dalteparin on venous thromboembolism (VTE) recurrence and bleeding in patients with VTE associated with gastrointestinal (GI) or genitourinary cancer.
The aim of the study is to determine the ability of abelacimab to reduce blood clotting with possibly fewer bleeding episodes. -
May 7, 2025Pamplona/MadridIn recruitment
0209-01 Clinical trial of CPI-0209 in patients with advanced solid tumors and lymphomas
The aim of conducting this trial is to find a dose of CPI-0209 whose side effects are acceptable and which may be useful in the treatment of patients with advanced tumors. Another objective of the trial is to monitor blood levels of CPI-0209. -
May 7, 2025Pamplona/MadridIn recruitmentEarly phase
LATE-R-GEL-23 Multicenter, open-label, single-arm, multicenter phase II clinical trial to evaluate the efficacy of axicabtagene ciloleucel in patients with late relapsed diffuse large B-cell lymphoma
The aim of the study is to evaluate the efficacy of the study treatment, axicabtagene ciloleucel, when administered to patients with aggressive BGCL as a second line (meaning that the patient must have received another treatment before). -
April 28, 2025Pamplona/MadridIn recruitmentEarly phase
GO44537 Clinical trial to evaluate the safety, pharmacokinetics and activity of RO7656594 in patients with advanced or metastatic prostate cancer.
The objective of this study is to evaluate RO7656594 at different doses to determine if it is safe and how it is processed by your body. The study consists of two parts: a dose-finding stage and a scale-up stage. -
April 28, 2025MadridIn recruitment
MK-2870-022 Phase 3 clinical trial to evaluate the efficacy and safety of maintenance therapy with sacituzumab tirumotecan versus standard therapy in platinum-sensitive recurrent ovarian cancer.
The main objective is to evaluate the safety and tolerability of tirumotecan sacituzumab in maintenance treatment with bevacizumab. -
April 9, 2025Pamplona/MadridIn recruitment
BET-PSMA-001 Randomized, multicenter, crossover study of single-patient imaging and dosimetry testing of lutetium (177Lu) rhPSMA-10.1 and lutetium (177Lu) vipivotide tetraxetane (Pluvicto®) in patients with metastatic prostate cancer in
This study is being conducted to learn more about injectable rhPSMA-10.1 lutetium (177Lu) (the "study drug") in men with prostate cancer that has progressed during or after prior treatment. -
March 31, 2025Pamplona/MadridIn recruitment
LOXO-BTK-20030 Clinical trial of pyrtobrutinib (LOXO-305) compared to ibrutinib in patients with chronic lymphocytic leukemia/small cell lymphocytic lymphoma (BRUIN-CLL-314).
The objectives of this clinical trial are as follows: - To determine the response of CLL/LLCP patients to treatment with pyrtobrutinib (group A) compared to ibrutinib (group B). - Determine the duration of beneficial effects of treatment with the study drugs (including how long patients live). - Determine safety and tolerability in group A and group B. - Determine how patients in group A are doing compared to those in group B. -
March 31, 2025Pamplona/MadridIn recruitmentEarly phase
J2N-MC-JZNX Phase II clinical trial to evaluate the efficacy and safety of Pirtobrutinib in participants with leukemia who have previously received treatment with a covalent Bruton's tyrosine kinase inhibitor.
Clinical trial to compare the overall response rate of: - pirtobrutinib 200 mg vs. 120 mg - pirtobrutinib 200 mg vs. 60 mg -
March 31, 2025PamplonaIn recruitment
RMC-6236-302 Phase III, multicenter, open-label, randomized, open-label clinical trial to evaluate RMC-6236 in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDCA).
The purpose of a trial is to collect information about the investigational drug: RMC-6236 -
March 25, 2025Pamplona/MadridIn recruitment
GRWD5769-ST-01 ERAP-1-mediated immunopeptidome-targeted trial
The main objective of this clinical trial is to determine the safety and efficacy of the study drug 12GRWD5769, alone or in combination with another drug called Libtayo® (cemiplimab), against advanced or metastatic malignant solid tumors.